SecBot Intelligence Feed

Three insiders at CRISPR Therapeutics sold a total of ~$3.15M in open-market sales within a week, including the CEO ($2.38M), a director ($720K), and the general counsel ($51K). The CEO's sale is the largest and most notable, occurring at ~$49.78 per share. While the dollar amount is modest relative to the company's market cap (likely <0.5%), the involvement of the CEO in a concentrated cluster warrants attention.

A strong institutional cluster formed in ILMN during Q3 2026, with 5 active managers accumulating $488.9M net in new positions, overwhelmingly led by Ninety One UK which more than doubled its stake to $372.2M. Two small sellers trimmed a combined $1.3M, making this a near-unanimous bullish signal from active asset managers. The cluster suggests a shared thesis around Illumina's post-Grail turnaround or core sequencing recovery, though the 45-day reporting lag means these positions may have already been adjusted.

Three CRISPR Therapeutics insiders, including the CEO and General Counsel, sold a total of ~$973K in open-market sales on October 14, 2026, following derivative exercises on October 13. The CEO's sale of $202K and the director's sale of $720K represent a cluster of selling that is notable in absolute dollar terms but modest relative to the company's market cap. The sales are not clearly plan-driven and follow option exercises, raising a mild caution flag for near-term sentiment.

Recursion Pharmaceuticals is offering 61,540,000 shares of Class A common stock at $3.25 per share, raising approximately $187.2 million in net proceeds. The offering is priced at a 13.1% discount to the last closing price of $3.74 and represents significant dilution of ~11.5% to existing shareholders. Proceeds will fund clinical programs including a registrational study for REC-4881 in FAP and dose expansion for REC-1245, as well as platform advancement and runway extension into 2029.

Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at $3.25/share, alongside positive clinical data updates (REC-4881 FAP data showing 47% median polyp reduction, REC-1245 partial responses in endometrial cancer) and a Sanofi milestone ($10M payment for optioned immunology development candidate). The offering extends cash runway into 2029 but causes ~12% dilution from the ~532M pre-offering share base. The prior quarter (Q2 2026) showed revenue of $7.7M (down 60% YoY from $19.2M) and a net loss of $131M (EPS -$0.25 vs consensus -$0.23, a miss).

Recursion Pharmaceuticals announced that Sanofi has optioned the first development candidate from their multi-program collaboration, triggering a $10 million milestone payment. This brings total upfront and milestone payments from Sanofi to $144 million, with over $300 million in additional milestones possible. The candidate, a potential first-in-class oral small molecule for inflammatory disease, will enter Phase 1 in 2027 with Sanofi funding development. The news is positive for the collaboration's progress but is tempered by the concurrent $200 million equity offering that dilutes existing shareholders.

Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per share, diluting existing shareholders by approximately 23% based on pre-offering shares outstanding. The offering, which closed the next day, extends cash runway into 2029 but represents a significant near-term dilution event.

Recursion Pharmaceuticals announced a $200 million underwritten common stock offering alongside positive clinical data updates for REC-4881 in FAP and REC-1245 in solid tumors, plus a $10 million milestone from Sanofi for optioning a development candidate. The capital raise extends cash runway into 2029 but dilutes existing shareholders, while the clinical data and partnership milestone provide validation of the platform.

Recursion Pharmaceuticals is filing a preliminary prospectus supplement for a $200 million underwritten public offering of Class A common stock. The filing also discloses positive clinical data for REC-4881 in FAP and initial data for REC-1245, and a $10 million milestone payment from Sanofi for optioning a development candidate. The offering will dilute existing shareholders and extends cash runway into 2029.

Six Twist Bioscience insiders, including the CEO, President/COO, and CFO, sold a combined $17.86M in shares over a one-week window. The CEO alone sold $8.64M. This is a large, concentrated sell cluster by top executives, which typically signals a bearish outlook on the stock's near-term prospects.

A mixed institutional cluster for Illumina in Q2 2026 shows 54 buyers accumulating $1.02B net (dominated by Fidelity's $604.7M addition and strong adds from MFS, Goldman Sachs, and Jane Street) while 38 sellers trimmed only $23.1M net, with notable activist Corvex trimming 26% of its stake.

Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401, a first-in-human in vivo gene editing therapy for hyperlipidemia. The company also released new preclinical data showing ~90% LDL-C reduction maintained over 10 months in non-human primates, to be presented at AHA Scientific Sessions 2026. Initial safety data is expected in Q1 2027, with topline results later in 2027.

Director James R. Gibson II filed a Form 144 notice of intent to sell up to 661,815 shares of Pacific Biosciences of California, Inc. (PACB), with an approximate market value of $1,899,409.05 based on the filing date. The shares are sourced from exercised stock options and vested restricted stock units, indicating a planned liquidation of a significant portion of his holdings.

NeoGenomics announced a planned CEO succession: President/COO Warren Stone will become CEO effective Jan 4, 2027, while current CEO Tony Zook transitions to Executive Chairman. The company also released preliminary Q3 2026 revenue of approximately $209M (+11% YoY) with NGS growth of ~28%, and expects to raise full-year revenue guidance at the midpoint. The leadership transition is orderly and the preliminary revenue beat is positive, but the EPS miss (-9.8% vs consensus) tempers the outlook.

Two insiders at Twist Bioscience sold a combined $2.08M in open-market sales on the same day, including the Chief Accounting Officer and a senior executive. The total value represents approximately 0.64% of the company's $326M market cap, a modest but notable cluster.

Fate Therapeutics received a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 RECLAIM-LN potentially registrational trial of FT819 off-the-shelf CAR T-cell therapy in lupus nephritis. The non-dilutive funding provides cash runway support for a key clinical catalyst but does not change the binary risk of the Phase 2 data readout.

Two CRISPR Therapeutics insiders—Director Ali Behbahani and General Counsel James Kasinger—sold a combined $1.41M in open-market sales over a one-week window. The sales represent ~0.43% of the company's market cap, a modest but notable cluster. No 10b5-1 plan is indicated, and the sales are not tax- or vesting-related, suggesting potential bearish conviction ahead of upcoming catalysts or earnings.

CEO Emily Leproust executed a massive derivative exercise and open-market sale of ~$55M in TWST stock on September 17, 2026, followed by a smaller $279K sale on September 21. The SVP of HR also sold $49K. The CEO's sales are overwhelmingly the dominant signal, but the sheer size and pattern suggest a planned exercise-and-sell program, not opportunistic selling. The cluster is notable for its dollar magnitude but likely reflects a pre-arranged 10b5-1 plan or tax-related disposition.

Recursion Pharmaceuticals amended its Master Agreement with Tempus AI, extending the term from five to six years and eliminating Recursion's right to terminate for convenience. Annual license fees were reduced from $42M to $14M for years 3-5, with at least $4M payable in cash. Separately, Recursion granted Tempus a non-exclusive license to its TxFM RNA model for oncology use for a $12M fee, providing a new revenue stream.

Bionano Genomics presented an investor deck at the H.C. Wainwright conference, highlighting Q2 2026 revenue of $8.2M (above guidance of $7.5-$7.8M), a raised FY2026 guidance range to $31-$33M, and a long-range plan projecting EBITDA break-even by Q4 FY27. The presentation also noted the retirement of JGB debt and progress on Medicare coverage for its OGM technology. While the Q2 beat and raised guidance are positive, the company remains pre-profitability with a $14M market cap and a history of going-concern disclosures, tempering the bullish signal.

Bionano Genomics highlighted three new peer-reviewed publications demonstrating that its optical genome mapping (OGM) technology detects clinically significant structural variants in high-risk myeloid malignancies (MDS, AML, t-MN) that are missed by standard karyotyping. The studies, from MD Anderson, University of Oulu, and Josep Carreras Institute, link OGM findings to survival outcomes and suggest OGM could refine risk stratification beyond current classification systems. This is a positive clinical validation event for OGM adoption, but the press release contains no financial data, no new product launches, and no regulatory approvals — it is a research-use-only announcement with no immediate revenue impact for the $14M market cap company, which has a going-concern risk noted in the forward-looking statements.

Director John R. Stuelpnagel filed a Form 144 notice of intent to sell 20,000 shares of Class A common stock, with an estimated aggregate market value of approximately $1.24 million based on a recent sale price of ~$61.75. The shares were originally granted as founder shares in 2017. This is a relatively small sale relative to the company's $8.0B market cap, but it follows a recent sale of the same number of shares on August 11, 2026, and comes amid elevated insider selling activity (9 sales totaling $4.1M in the past 30 days). The filing signals ongoing insider monetization, though the director's role and modest proportional size limit the bearish signal.

Director Keith Meister sold ~$4.0M in shares on Aug 19, and SVP Jakob Wedel Christensen sold $198K on Aug 18, totaling $4.22M in insider selling over a one-week window. While the dollar amount is modest relative to ILMN's $32.2B market cap (0.013%), the cluster is dominated by a single director's open-market sales, which are not routine 10b5-1 plan sales. The selling follows a period of heavy insider sales ($64.3M in the prior 30 days) and occurs without any disclosed catalyst, suggesting potential concern about valuation or upcoming news.

A mixed institutional cluster in TXG for 2026-Q2 shows 12 buyers adding $283.3M in new holdings, led by major quant and asset-manager funds (Citadel, Point72, Morgan Stanley, Jane Street), while 7 sellers trimmed $38.4M, led by Millennium's near-exit. The strong buying from active quant funds (Citadel doubling to $106.6M, Point72 new $71M, D.E. Shaw doubling) suggests a shared thesis around near-term catalysts or undervaluation, partially offset by Millennium's aggressive reduction. The cluster is dominated by active managers, not passive rebalancing, giving the buying signal moderate conviction despite the mixed net direction.

Eight institutional investors accumulated $59.7M in BEAM during Q2 2026, led by Morgan Stanley doubling its stake to $67M, while two smaller sellers trimmed $1.2M. The cluster is dominated by active asset managers with strong conviction (6 DOUBLED positions), but the 45-day reporting lag means positions may have been unwound. No insider open-market buying corroborates the institutional accumulation, weakening the conviction signal per the confluence score of 21/100 (divergent). The cross-filing amplifier (inst-earnings + inst-offering context) supports a slightly elevated score, but the historical underperformance of high-score BEAM calls and the lack of insider buying keep the impact at 5 rather than 6+.

Twist Bioscience CEO Emily Leproust sold $14.2M of stock via a derivative exercise-and-sell transaction, while two directors and another executive also sold shares totaling ~$18.1M in the week following a strong Q3 earnings beat. The cluster is dominated by the CEO's open-market sale, which is the largest insider sell at the company in the past 30 days ($18.7M total prior). The sales follow an earnings report that beat consensus and raised guidance, but the CEO's sale is a large, non-10b5-1 disposition that may signal limited upside at current levels near $125.

Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for lupus nephritis. The trial targets ~53 patients with enrollment expected to complete by 1H2028, supported by RMAT designation and FDA CMC pilot program. This is a positive clinical milestone but no efficacy data is expected for 12-18 months.

Bionano Genomics reported Q2 2026 revenue of $8.2M, up 21% YoY and above its own guidance of $7.5-7.8M, driven by 31% consumables growth and 27% flow cell sales growth. The company fully retired its secured convertible debentures, eliminating all secured debt. However, net loss widened to $7.4M from $6.9M, and the company remains unprofitable with ongoing cash burn.

Director Keith A. Meister sold a large block totaling ~$149M over two days, representing roughly 0.5% of ILMN's market cap - a material divestiture. No insider buys were made on the open market, and the only other insider trade was the Chief Legal Officer selling a small stake. This is a clear seven-figure selling cluster with no offsetting buying.

Director Keith A. Meister sold a massive $150.4M worth of ILMN common stock over two days (Aug 4-5), plus an additional $1.42M in a separate transaction from the same window, while Chief Legal Officer Scott M. Davies sold $123K. The cluster total of ~$151.9M represents ~0.52% of ILMN's $29.3B market cap, a significant concentration in a single director. C-suite participation is absent (only a director and the CLO), limiting the informational signal below what a C-suite cluster would carry. Per the insider-sales literature, cluster sales are not reliably informative above the proportionality band, and the sheer size here is notable but the identity (director, not CEO/CFO) tempers bearish conviction.

Intellia Therapeutics reported Q2 2026 results with a net loss of $106.6M (-$0.80 EPS, -2.6% miss vs consensus) and collaboration revenue of $7.7M (-46% YoY, 41% miss). The primary stock-moving event is the positive Phase 3 HAELO data for lonvo-z in HAE, published in NEJM, with BLA submission expected in H2 2026 and U.S. launch in H1 2027. The company ended Q2 with $628M cash, funding operations into 2028.

Two insiders at Fate Therapeutics, including the CEO, sold a combined $204K worth of shares in open-market transactions on August 4, 2026. While the dollar amount is modest relative to the $303M market cap, multi-executive selling at a struggling biotech with a weak historical follow-through on our calls warrants caution.

Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 consensus), a miss on both top and bottom lines. The headline financials are weak, but the stock is likely to move on the operational catalyst: Genentech exercised the first Validated Target Option under the neuroscience collaboration, advancing a novel target into early discovery—a key platform validation. The company also lowered 2026 cash operating expense guidance to <$375M (from <$390M), extending runway into early 2028 without additional financing.

Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 consensus), a miss on both top and bottom lines. The headline financials are weak, but the stock is likely to move on the operational catalyst: Genentech exercised the first Validated Target Option under the neuroscience collaboration, advancing a novel target into early discovery—a key platform validation. The company also lowered 2026 cash operating expense guidance to $375M (from $390M), extending runway into early 2028 without additional financing.

CRISPR Therapeutics reported Q2 2026 GAAP EPS of -$0.94, beating consensus of -$1.10 by 14.5%, as CASGEVY revenue reached $76M (+151% YoY) and net loss narrowed to $91.2M from $208.5M a year ago. The FDA approval of CASGEVY for children aged 2+ and the advancement of in vivo and siRNA pipeline programs reinforce the company's commercial and clinical momentum.

A mixed institutional cluster emerged in 10x Genomics during Q1 2026: 14 buyers (net adding $235M) and 13 sellers (net reducing $51.8M), for a net inflow of ~$183M. The buying was concentrated in Fidelity's massive 48.9% add (+$182M) and a new $21M position by Balyasny, while sellers included Wellington's full exit (-$23.6M) and trimming by BofA and RenTech. The active-manager buying carries stronger conviction than the passive-dominant sell side, but the cluster lacks any insider open-market buying to corroborate the thesis. At a $5B market cap, the institutional accumulation is notable but mixed signals prevent a strong directional read.

A cluster of insider selling at Beam Therapeutics materialized over June 26-30, 2026, totaling $8.95M. The CEO exercised stock options and sold shares in a typical cashless-exercise pattern, while the 10% owner FMR LLC sold $8.87M — a meaningful 0.26% of market cap. This is a mixed signal: the CEO's trades are routine option exercises, but FMR's large sale is a notable reduction of a top stake.

CEO John M. Evans exercised options and sold shares worth ~$1.26M, while 10% owner FMR LLC sold 251,488 shares (~$8.87M) in a cluster sale totaling $9.34M, representing ~0.27% of BEAM's $3.4B market cap. The CEO's sales are likely liquidity-related from option exercises, but the large FMR block sale adds bearish pressure.

FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel near-exiting a $5.1M position) overwhelming 2 quant buyers (RenTech and Two Sigma doubling small positions). Net selling of ~$6M signals fading conviction among major holders, consistent with the stock's small $218M market cap and ongoing sector headwinds.

A mixed institutional cluster in Editas Medicine (EDIT) for Q4 2025 shows quant funds D.E. Shaw and Renaissance Technologies aggressively doubling their positions (combined +$3.7M), while mega-passive sellers BofA, Morgan Stanley, and Dimensional Fund Advisors trimmed or nearly exited, reducing holdings by ~$8.1M. The net effect is modest buying ($3.5M) against heavy selling, reflecting divergent views on the gene-editing biotech's near-term prospects.

Alka Chaubey, Ph.D., resigned as Chief Medical Officer of Bionano Genomics, effective July 5, 2026. The filing provides no reason for the departure and no replacement is named, which is a minor negative signal for the company's executive bench depth.

Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid tumors, at ASCO 2026. In two heavily pre-treated KRASwt metastatic colorectal cancer patients, FT836 plus cetuximab without conditioning chemotherapy showed a 19% tumor reduction (Case 1) and a 52% liver lesion reduction (Case 2), with no DLTs, CRS, ICANS, or GvHD across nine patients. The data demonstrate first-in-human proof of trafficking and persistence in tumor tissue without lymphodepletion, but the sample is tiny (n=9 safety, n=5 efficacy-evaluable, n=2 with anti-tumor activity) and early-stage, limiting immediate stock-moving impact.

A substantial insider selling cluster at Twist Bioscience, concentrated on May 21-26, 2026, with CEO Emily Leproust alone selling ~$3.1M in open-market shares after exercising options. The cluster spans the C-suite (CEO, COO, CFO, Chief Accounting Officer), SVP of HR, and a director. Total open-market sales exceed $3.9M, representing approximately 0.1% of the $4.0B market cap, placing it at the modest-to-notable boundary. The pattern suggests a coordinated response to a single event — likely a planned post-blackout or 10b5-1 window opening following earnings, a press release, or an offering — consistent with the cross-filing amplifications flagged by the actuarial model.

Bionano Genomics fully retired its $20M Senior Secured Convertible Debentures using cash on hand, eliminating all secured debt, liens, and restrictive covenants. This strengthens the balance sheet and provides greater financial flexibility, though the cash drain raises questions about runway given the company's going-concern risk noted in forward-looking statements.